N/A
Completed N=11
Electromyography in Patients on Chronic Pyridostigmine Therapy
Source: ClinicalTrials.gov NCT02364180 ↗Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcomePrimary: Percent Change in the Amplitude of Evoked Compound Muscle Action Potential by Electromyography Between the First to Fifth Response — 0 percent change
Summary
We intend to measure evoked EMG at two sites in subjects who are chronically taking pyridostigmine.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in the Amplitude of Evoked Compound Muscle Action Potential by Electromyography Between the First to Fifth Response |
— | — |
Eligibility Criteria
Inclusion Criteria
- Subjects who have been taking pyridostigmine for the treatment of any condition other than myasthenia gravis
Exclusion Criteria
- Subjects taking pyridostigmine for the treatment of myasthenia gravis will be excluded.
Data sourced from ClinicalTrials.gov (NCT02364180). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.